Clinical

Dataset Information

0

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

ABSTRACT: This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

DISEASE(S): Neoplasm, Residual,Adenocarcinoma,Colorectal Cancer,Colon Adenocarcinoma,Colonic Neoplasms

PROVIDER: 2380082 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
| S-EPMC9265001 | biostudies-literature
Unknown Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.
| S-EPMC8616165 | biostudies-literature
Unknown Establishing PNB-qPCR for quantifying minimal ctDNA concentrations during tumour resection.
| S-EPMC5566323 | biostudies-literature
Unknown Minimal Residual Disease, Metastasis and Immunity.
| S-EPMC7909268 | biostudies-literature
Unknown Minimal residual disease in acute myeloid leukaemia.
| S-EPMC4163748 | biostudies-literature
Clinical Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
| 2386782 | ecrin-mdr-crc
Unknown Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
| S-EPMC6561896 | biostudies-literature
Transcriptomics Towards minimal residual disease-directed therapy in melanoma
2018-07-18 | GSE116237 | GEO
Proteomics Minimal Change Disease: a proteomics approach
2024-03-12 | MSV000094293 | MassIVE
Clinical TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
| 2719898 | ecrin-mdr-crc